Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
about
Emerging mechanisms of fluoroquinolone resistanceBreakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone targetStructure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transportThe difficult case of crystallization and structure solution for the ParC55 breakage-reunion domain of topoisomerase IV from Streptococcus pneumoniaeExpression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolonesMycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activityExploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolonesContribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniaeDual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.A synthetic lethal approach for compound and target identification in Staphylococcus aureusFunctional Analyses of the Toxoplasma gondii DNA Gyrase Holoenzyme: A Janus Topoisomerase with Supercoiling and Decatenation Abilities.Mechanisms of drug resistance: quinolone resistance.PprA Protein Is Involved in Chromosome Segregation via Its Physical and Functional Interaction with DNA Gyrase in Irradiated Deinococcus radiodurans BacteriaIn vivo and in vitro patterns of the activity of simocyclinone D8, an angucyclinone antibiotic from Streptomyces antibioticus.Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasisCiprofloxacin dimers target gyrase in Streptococcus pneumoniae.Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IVClerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage.Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage.Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance.
P2860
Q24644842-D3AE0F1A-3091-4B2C-AE68-2F0015D947CCQ27303056-6671242E-BE0B-4415-B36E-428B7104000BQ27679776-B06F49FA-9D63-4EDC-9A36-C243659F961AQ28473592-F3D516B4-90CF-4024-9706-489F9550C20FQ28484902-1AA20ACA-E9A7-4C41-B3B1-76B70EDAC47DQ28486793-232AD671-E55D-4862-947D-7C01A92893AFQ28828291-5B210405-8D4D-4660-8A2A-C51D115EB05BQ33757558-D079EB27-FB34-4647-85A9-07C13C4D93D5Q33770013-96614AAC-A56D-4FDB-8F0C-A5A8BEAA58EDQ33978324-0FF61C09-4797-4B66-8A67-924F2E70C89BQ33980747-29FD952D-746D-4663-87F2-02EB019A1142Q33983092-2721E0EF-A480-4819-BD6C-BB523BA76A43Q34142238-3415DFEF-47EB-4B14-A66B-86EA1EB0060BQ34721556-24AEA35D-FAD4-486F-BDA7-920EAA005445Q35855932-640BFD97-042F-4EE1-BB88-C18172575D0DQ36100114-B01711A1-AE42-4414-8283-95A1AFC8A158Q36225422-B75C7412-2FCF-4657-9582-067475D9B613Q36891270-DBF4EB9F-1271-488B-8599-CCEB2C5C8D4FQ37190713-F2EE8CD9-98F0-42A7-992E-2DC5AC358D21Q38906198-0A79C923-63DE-448D-BAD3-A5C38F42A55FQ39472798-7766D97D-D321-4605-8141-E327978093ECQ39476686-F997E42D-0AA1-43F0-B92F-A3DDC793CE77Q39477371-1E64677D-6911-4862-BBF4-EB7D84806A54Q39478563-BFDD8FE4-26C2-449C-943B-FBD1E9895D93Q39478835-9E7F72AE-1ACF-406C-82CE-882AE4D565B7Q39537237-B6971AED-D6B7-4D6A-9EE0-6AA6E2F83980Q39651301-5D342731-8573-4FA6-A58D-6AE18DF89A7BQ39651324-8A0D2299-8CB8-405B-A5E0-71820C75ABB6Q39651895-CE0CB2BD-CB90-4D92-B91A-C8A19DB0F7A9Q39743472-CE667E20-EF02-47F8-828B-B1472970DF6DQ40882705-86BFBEE9-7B53-460B-A6C4-C597000CEF5FQ41825585-75A22983-1C18-47A3-98B5-1D8614ABFA28Q41848451-78AFEB72-C7E3-4266-84FC-23A50941EBA8Q41859520-6F21F0D0-5C53-4E00-A83C-9251D272E42AQ42041266-E271AD7F-5587-45FF-B1C8-DF5255DE44C9Q42111122-BE6FBD97-F181-4CEC-B292-31E10E4B43C0Q42111571-533024D4-85C3-4EAC-8E2F-CF2082174EE0Q42264322-08D2423A-16B2-4274-A50F-597DFC5866A2Q42872445-969CD0B7-33DE-4EFD-B63E-20D3E8C02183Q46335874-1815BC29-EBDF-4EB7-B404-AE13D4AE6686
P2860
Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@en
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@nl
type
label
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@en
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@nl
prefLabel
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@en
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@nl
P2860
P1476
Streptococcus pneumoniae DNA g ...... nhibition by fluoroquinolones.
@en
P2093
P2860
P304
P407
P577
1999-05-01T00:00:00Z